1-20 of 47
Keywords: Acromegaly
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Neuroendocrinology 1.
Published Online: 16 February 2024
...Juan Chen; Zhigao Xiang; Zhuo Zhang; Yan Yang; Kai Shu; Ting Lei Introduction: Acromegaly patients, in addition to the most prominent physical and endocrine changes, also exhibit a higher risk of cognitive dysfunction. However, the reasons and mechanisms underlying cognitive impairments...
Journal Articles
Neuroendocrinology (2024) 114 (1): 51–63.
Published Online: 12 September 2023
...Paulina Kober; Julia Rymuza; Szymon Baluszek; Maria Maksymowicz; Aleksandra Nyc; Beata J. Mossakowska; Grzegorz Zieliński; Jacek Kunicki; Mateusz Bujko Introduction: Growth hormone secretion by sporadic somatotroph neuroendocrine pituitary tumors (PitNETs) is a major cause of acromegaly...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Neuroendocrinology (2021) 111 (4): 388–402.
Published Online: 16 April 2020
...Leticia P. Leonart; Bruno S. Riveros; Murray D. Krahn; Roberto Pontarolo Objectives: To conduct a cost-utility analysis comparing drug strategies involving octreotide, lanreotide, pasireotide, and pegvisomant for the treatment of patients with acromegaly who have failed surgery, from a Brazilian...
Journal Articles
Neuroendocrinology (2020) 110 (9-10): 882–888.
Published Online: 27 February 2020
... domains and determines their future life. Understanding that this may occur is important, and health care providers should offer information to prepare the patient for this difficult journey, especially in the case of acromegaly, Cushing disease, or hypopituitarism. In order to maintain a good quality...
Journal Articles
Journal Articles
Neuroendocrinology (2020) 110 (5): 328–337.
Published Online: 19 July 2019
... associated with endocrinal disorders using a deep-learning approach to facilitate the process of diagnosis and follow-up. Methods: We collected facial images of patients with hypercortisolism and acromegaly, and we augmented these images with additional negative samples from public databases. A model...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Neuroendocrinology (2016) 103 (1): 32–41.
Published Online: 05 November 2015
...Michael Buchfelder; Sven-Martin Schlaffer Since the establishment of transsphenoidal microsurgery as the operative treatment of choice in most patients with acromegaly 40 years ago, a few novel technical developments have evolved. Their application, utility and efficacy will be briefly discussed...
Journal Articles
Neuroendocrinology (2016) 103 (1): 75–85.
Published Online: 28 July 2015
...Andrew S. Powlson; Mark Gurnell Treatment goals in acromegaly include symptom relief, tumour control and reversal of the excess morbidity and mortality associated with the disorder. Cardiovascular complications include concentric biventricular hypertrophy and cardiomyopathy, hypertension, valvular...
Journal Articles
Neuroendocrinology (2016) 103 (1): 42–49.
Published Online: 17 June 2015
...Mark J. Hannon; Ariel L. Barkan; William M. Drake Radiotherapy has, historically, played a central role in the management of acromegaly, and the last 30 years have seen substantial improvements in the technology used in the delivery of radiation therapy. More recently, the introduction of highly...
Journal Articles
Neuroendocrinology (2016) 103 (1): 96–105.
Published Online: 29 April 2015
...Jakob Dal; Edward O. List; Jens Otto L. Jørgensen; Darlene E. Berryman Patients with active acromegaly are frequently insulin resistant, glucose intolerant, and at risk for developing overt type 2 diabetes. At the same time, these patients have a relatively lean phenotype associated...
Journal Articles
Neuroendocrinology (2016) 103 (1): 59–65.
Published Online: 19 March 2015
...Sebastian J.C.M.M. Neggers; Ammar Muhammad; Aart Jan van der Lely Historically, medical treatment of acromegaly has mainly been used as an adjuvant therapy after surgery. In the last decades, an increased range of medical therapy options has been available. Somatostatin analogues have become...
Journal Articles
Neuroendocrinology (2015) 102 (1-2): 8–17.
Published Online: 16 March 2015
...Susan L. Samson Background: Acromegaly is an insidious neuroendocrine disorder caused by hypersecretion of growth hormone (GH) by a somatotroph adenoma. Somatostatin receptor ligands (SRLs) are recommended as first-line medical therapy in patients for whom surgery has failed or is contraindicated...
Journal Articles
Neuroendocrinology (2016) 103 (1): 50–58.
Published Online: 12 February 2015
...Philippe Chanson Treatment of acromegaly aims to correct (or prevent) tumor compression of surrounding tissues by excising the disease-causing lesion and reduce growth hormone (GH) and IGF-1 levels to normal values. When surgery (the usual first-line treatment) fails to correct GH/IGF-1...